Want to see HK:2696 full AI Analyst Report?
Shanghai Henlius Biotech, Inc. Class H (2696) Ratios
Shanghai Henlius Biotech, Inc. Class H Ratios
HK:2696's free cash flow for Q2 2026 was $243.25M. For the 2026 fiscal year, HK:2696's free cash flow was decreased by $-36.46M and operating cash flow was $279.70M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.71 | 0.50 | 0.53 | 0.44 | 0.56 |
| Quick Ratio | 0.58 | 0.35 | 0.38 | 0.29 | 0.41 |
| Cash Ratio | 0.16 | 0.15 | 0.19 | 0.13 | 0.05 |
| Solvency Ratio | 0.15 | 0.15 | 0.11 | -0.06 | -0.16 |
| Operating Cash Flow Ratio | 0.24 | 0.25 | 0.21 | 0.20 | 0.03 |
| Short-Term Operating Cash Flow Coverage | 0.53 | 0.50 | 0.39 | 0.40 | 0.06 |
| Net Current Asset Value | $ -4.92B | $ -5.07B | $ -5.04B | $ -5.10B | $ -3.23B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.29 | 0.34 | 0.41 | 0.41 | 0.37 |
| Debt-to-Equity Ratio | 0.91 | 1.21 | 1.87 | 2.25 | 1.14 |
| Debt-to-Capital Ratio | 0.48 | 0.55 | 0.65 | 0.69 | 0.53 |
| Long-Term Debt-to-Capital Ratio | 0.24 | 0.24 | 0.34 | 0.37 | 0.27 |
| Financial Leverage Ratio | 3.12 | 3.52 | 4.52 | 5.45 | 3.12 |
| Debt Service Coverage Ratio | 0.55 | 0.43 | 0.31 | -0.12 | -0.44 |
| Interest Coverage Ratio | 8.18 | 7.64 | 5.71 | -5.95 | -7.84 |
| Debt to Market Cap | 0.12 | 0.28 | 0.53 | 0.56 | 0.24 |
| Interest Debt Per Share | 6.77 | 6.94 | 7.70 | 6.98 | 5.04 |
| Net Debt to EBITDA | 2.27 | 2.51 | 3.41 | -9.67 | -3.67 |
| Profitability Margins | |||||
| Gross Profit Margin | 74.77% | 73.10% | 72.64% | 73.73% | 68.93% |
| EBIT Margin | 12.26% | 15.14% | 11.71% | -18.30% | -51.82% |
| EBITDA Margin | 18.70% | 20.02% | 16.89% | -9.66% | -39.93% |
| Operating Profit Margin | 12.26% | 16.41% | 11.71% | -19.55% | -39.54% |
| Pretax Profit Margin | 12.18% | 14.78% | 10.56% | -21.58% | -56.87% |
| Net Profit Margin | 12.08% | 14.33% | 10.12% | -21.63% | -58.49% |
| Continuous Operations Profit Margin | 12.08% | 14.33% | 10.12% | -21.63% | -58.49% |
| Net Income Per EBT | 99.25% | 97.00% | 95.86% | 100.20% | 102.85% |
| EBT Per EBIT | 99.34% | 90.07% | 90.17% | 110.40% | 143.82% |
| Return on Assets (ROA) | 6.51% | 7.74% | 5.51% | -7.79% | -13.72% |
| Return on Equity (ROE) | 20.33% | 27.23% | 24.91% | -42.49% | -42.85% |
| Return on Capital Employed (ROCE) | 11.01% | 16.87% | 13.06% | -16.02% | -15.79% |
| Return on Invested Capital (ROIC) | 8.45% | 11.21% | 7.93% | -9.75% | -11.50% |
| Return on Tangible Assets | 12.99% | 15.65% | 8.22% | -15.14% | -27.81% |
| Earnings Yield | 2.88% | 6.78% | 7.54% | -11.35% | -10.19% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.60 | 6.35 | 7.39 | 7.06 | 5.69 |
| Payables Turnover | 2.02 | 2.11 | 2.71 | 1.18 | 1.36 |
| Inventory Turnover | 2.75 | 2.11 | 1.95 | 1.12 | 1.24 |
| Fixed Asset Turnover | 2.58 | 2.12 | 2.03 | 1.44 | 1.01 |
| Asset Turnover | 0.54 | 0.54 | 0.54 | 0.36 | 0.23 |
| Working Capital Turnover Ratio | -3.35 | -2.33 | -2.07 | -1.56 | -2.43 |
| Cash Conversion Cycle | 53.82 | 57.27 | 101.96 | 70.63 | 89.74 |
| Days of Sales Outstanding | 101.28 | 57.47 | 49.41 | 51.72 | 64.16 |
| Days of Inventory Outstanding | 132.96 | 172.63 | 187.27 | 327.27 | 293.34 |
| Days of Payables Outstanding | 180.42 | 172.83 | 134.72 | 308.36 | 267.75 |
| Operating Cycle | 234.24 | 230.10 | 236.68 | 378.99 | 357.49 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 2.13 | 2.29 | 1.92 | 1.81 | 0.17 |
| Free Cash Flow Per Share | 1.58 | 0.74 | 0.07 | -0.71 | -1.94 |
| Dividend Paid and CapEx Coverage Ratio | 3.83 | 1.48 | 1.04 | 0.72 | 0.08 |
| Capital Expenditure Coverage Ratio | 3.83 | 1.48 | 1.04 | 0.72 | 0.08 |
| Operating Cash Flow Coverage Ratio | 0.32 | 0.34 | 0.26 | 0.27 | 0.03 |
| Operating Cash Flow to Sales Ratio | 0.17 | 0.22 | 0.19 | 0.31 | 0.05 |
| Free Cash Flow Yield | 3.07% | 3.35% | 0.50% | -6.26% | -10.78% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 34.86 | 14.74 | 13.27 | -8.81 | -9.81 |
| Price-to-Sales (P/S) Ratio | 4.20 | 2.11 | 1.34 | 1.91 | 5.74 |
| Price-to-Book (P/B) Ratio | 7.06 | 4.01 | 3.30 | 3.74 | 4.20 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 32.53 | 29.89 | 198.57 | -15.97 | -9.28 |
| Price-to-Operating Cash Flow Ratio | 24.05 | 9.74 | 6.91 | 6.24 | 106.83 |
| Price-to-Earnings Growth (PEG) Ratio | -13.16 | 0.30 | -0.07 | 0.29 | 3.69 |
| Enterprise Value Multiple | 24.71 | 13.06 | 11.36 | -29.39 | -18.05 |
| Enterprise Value | 30.80B | 14.97B | 10.35B | 9.13B | 12.12B |
| EV to EBITDA | 24.71 | 13.06 | 11.36 | -29.39 | -18.05 |
| EV to Sales | 4.62 | 2.62 | 1.92 | 2.84 | 7.21 |
| EV to Free Cash Flow | 35.82 | 37.00 | 283.70 | -23.80 | -11.65 |
| EV to Operating Cash Flow | 26.48 | 12.06 | 9.88 | 9.30 | 134.13 |
| Tangible Book Value Per Share | -4.03 | -4.31 | -1.96 | -4.97 | -2.49 |
| Shareholders’ Equity Per Share | 7.26 | 5.54 | 4.02 | 3.02 | 4.27 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.02 | 0.03 | 0.04 | -0.00 | -0.03 |
| Revenue Per Share | 12.21 | 10.53 | 9.88 | 5.93 | 3.13 |
| Net Income Per Share | 1.48 | 1.51 | 1.00 | -1.28 | -1.83 |
| Tax Burden | 0.99 | 0.97 | 0.96 | 1.00 | 1.03 |
| Interest Burden | 0.99 | 0.98 | 0.90 | 1.18 | 1.10 |
| Research & Development to Revenue | 0.23 | 0.18 | 0.21 | 0.43 | 0.61 |
| SG&A to Revenue | 0.40 | 0.40 | 0.07 | 0.11 | 0.17 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Income Quality | 1.44 | 1.51 | 1.84 | -1.41 | -0.09 |
Currency in CNY
